SAFETY, TOLERABILITY AND PHARMACOKINETICS OF NX-13 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY IN NORMAL HEALTHY VOLUNTEERS

Andrew Leber  1     Raquel Hontecillas  1     Nuria Tubau-Juni  1     Jyoti Chauhan  1     Jean-Frédéric Colombel  2     Simon Lichtiger  1     Josep Bassaganya-Riera  1    
1 Landos Biopharma, Inc., Blacksburg, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing